Iron: The new advances in therapy

被引:27
作者
Auerbach, Michael [1 ,2 ]
Goodnough, Lawrence Tim [3 ,4 ]
Shander, Aryeh [5 ]
机构
[1] Div Hematol & Oncol, Baltimore, MD USA
[2] Georgetown Univ, Sch Med, Washington, DC USA
[3] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA
[5] Englewood Hosp & Med Ctr, Dept Anesthesiol & Crit Care, Englewood, NJ USA
关键词
anaemia; iron; hepcidin; erythropoietin;
D O I
10.1016/j.bpa.2012.12.001
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Conditions known as iron-deficiency syndromes are very common in various patient populations, and they can adversely affect the outcomes of the patients, in addition to increasing their risk of getting transfused. Iron-deficiency syndromes include absolute iron deficiency (absence of storage iron), functional iron deficiency (when demand for iron exceeds the supply in face of intense stimulation erythropoiesis) and iron sequestration (in which existing storage iron becomes unavailable); these conditions often co-exist in hospitalised patients, making the diagnosis and management more difficult. Nonetheless, iron is emerging as a safe and effective therapy in patients suffering from these conditions. Notably, several intravenous iron formulations are available and they can be used safely and effectively to restore the body iron levels (possibly even in a single treatment episode). Data from ongoing clinical trials are expected to further establish the role of these products in treatment of patients with anaemia. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:131 / 140
页数:10
相关论文
共 79 条
[1]  
Acher P L, 2003, Colorectal Dis, V5, P145, DOI 10.1046/j.1463-1318.2003.00415.x
[2]   Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. [J].
Anker, Stefan D. ;
Comin Colet, Josep ;
Filippatos, Gerasimos ;
Willenheimer, Ronnie ;
Dickstein, Kenneth ;
Drexler, Helmut ;
Luescher, Thomas F. ;
Bart, Boris ;
Banasiak, Waldemar ;
Niegowska, Joanna ;
Kirwan, Bridget-Anne ;
Mori, Claudio ;
Rothe, Barbara von Eisenhart ;
Pocock, Stuart J. ;
Poole-Wilson, Philip A. ;
Ponikowski, Piotr .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (25) :2436-2448
[3]   Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms [J].
Annibale, B ;
Capurso, G ;
Chistolini, A ;
D'Ambra, G ;
DiGiulio, E ;
Monarca, B ;
DelleFave, G .
AMERICAN JOURNAL OF MEDICINE, 2001, 111 (06) :439-445
[4]   Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens [J].
Aronoff, GR ;
Bennett, WM ;
Blumenthal, S ;
Charytan, C ;
Pennell, JP ;
Reed, J ;
Rothstein, M ;
Strom, J ;
Wolfe, A ;
Van Wyck, D ;
Yee, J .
KIDNEY INTERNATIONAL, 2004, 66 (03) :1193-1198
[5]   Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin [J].
Ashby, Damien R. ;
Gale, Daniel P. ;
Busbridge, Mark ;
Murphy, Kevin G. ;
Duncan, Neill D. ;
Cairns, Tom D. ;
Taube, David H. ;
Bloom, Stephen R. ;
Tam, Frederick W. K. ;
Chapman, Richard ;
Maxwell, Patrick H. ;
Choi, Peter .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03) :505-508
[6]   Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial [J].
Auerbach, M ;
Ballard, H ;
Trout, JR ;
McIlwain, M ;
Ackerman, A ;
Bahrain, H ;
Balan, S ;
Barker, L ;
Rana, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1301-1307
[7]   A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients [J].
Auerbach, M ;
Winchester, J ;
Wahab, A ;
Richards, K ;
McGinley, M ;
Hall, F ;
Anderson, J ;
Briefel, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (01) :81-86
[8]   Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial [J].
Auerbach, M ;
Chaudhry, M ;
Goldman, H ;
Ballard, H .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (03) :257-260
[9]  
AUERBACH M, 1988, J LAB CLIN MED, V111, P566
[10]  
Auerbach M, 2011, SAFETY EFFICACY TOTA